Financing ·
Latigo Biotherapeutics, Inc. completed its initial public offering on August 10, 2026, selling 19,200,000 shares of…
LTGOLatigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. completed its initial public offering on August 10, 2026, selling 19,200,000 shares of common stock at $18.00 per share. The transaction generated approximately $345.6 million in aggregate gross proceeds before deducting underwriting discounts and estimated offering expenses. Concurrently, the company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws with the Secretary of State of Delaware to reflect its status as a public entity. Latigo Biotherapeutics operates in the biotechnology industry, focusing on the discovery and development of novel therapeutics.